CompletedNot Applicable

Study of DNA in Blood Samples From Patients With Neuroblastoma

United States329 participantsStarted 2007-06

Plain-language summary

This research trial studies is deoxyribonucleic acid (DNA) in blood samples from patients with neuroblastoma. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Serum samples from neuroblastoma (NB) patients obtained through the COG (and legacy Children's Cancer Group \[CCG\]/Pediatric Oncology Group \[POG\] Biology Studies) * The MYCN status on corresponding tumors have been determined using standard techniques; the panel of samples must be obtained from NB patients with and without MYCN amplification tumors * Cases will be drawn from clinical subsets at greatest likelihood to benefit from this testing ability, stage 1 and 2 NBs (both infants and toddlers), stage 4 patients under 18 months of age, and 4S patients

What they're measuring

Most appropriate MYCN/control ratio cutoff capable of determining positive and negative cases of neuroblastoma assessed by PCR

Timeframe: Up to 6 months

Limits of the procedure in non-metastatic patients and in those with reduced tumor burden

Timeframe: Up to 6 months

Trial details

NCT IDNCT00898391

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Disseminated Neuroblastoma trials